Binge eating disorder the USA, BED is present in 0.8% of male adults and 1.6% of female adults in a given year. Additionally, 30 to 40 percent of individuals seeking treatment for weight-loss can be diagnosed with binge eating disorder. The disorder was first described in 1959 by psychiatrist and researcher Albert Stunkard as "night eating syndrome" (NES). The term "binge eating" was coined to describe the same binging-type eating behavior but without the exclusive nocturnal component. There is generally less research on binge eating disorder in comparison to anorexia nervosa and bulimia nervosa. Binge eating disorder Binge eating disorder (BED) is an
Binge eating disorder is used for the treatment of moderate to severe binge eating disorder in adults. Three other classes of medications are also used in the treatment of binge eating disorder: antidepressants, anticonvulsants, and anti-obesity medications. Antidepressant medications of the selective serotonin reuptake inhibitor (SSRI) class such as fluoxetine, fluvoxamine, or sertraline have been found to effectively reduce episodes of binge eating and reduce weight. Similarly, anticonvulsant medications such as topiramate and zonisamide may be able to effectively suppress appetite. The long-term effectiveness of medication for binge eating disorder is currently unknown. Trials of antidepressants, anticonvulsants, and anti-obesity medications suggest that these